Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience.
carcinoma
diffusion magnetic resonance imaging
histological techniques
magnetic resonance imaging
pancreatic ductal
prognosis
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
13
12
2019
revised:
19
03
2020
accepted:
07
04
2020
pubmed:
15
4
2020
medline:
7
7
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
Patient stratification based on biological variation in pancreatic ductal adenocarcinoma (PDAC) subtypes could help to improve clinical outcome. However, noninvasive assessment of the entire tumor microenvironment remains challenging. In this study, we investigate the biological basis of dynamic contrast-enhanced (DCE), intravoxel incoherent motion (IVIM), and R2*-derived magnetic resonance imaging (MRI) parameters for the noninvasive characterization of the PDAC tumor microenvironment and evaluate their prognostic potential in PDAC patients. Patients diagnosed with treatment-naïve resectable PDAC underwent MRI. After resection, a whole-mount tumor slice was analyzed for collagen fraction, vessel density, and hypoxia and matched to the MRI parameter maps. MRI parameters were correlated to immunohistochemistry-derived tissue characteristics and evaluated for prognostic potential. Thirty patients were included of whom 21 underwent resection with whole-mount histology available in 15 patients. DCE K
Identifiants
pubmed: 32285559
doi: 10.1002/1878-0261.12688
pmc: PMC7463316
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2176-2189Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
Eur J Radiol. 2014 Apr;83(4):612-9
pubmed: 24418286
J Histochem Cytochem. 2003 May;51(5):575-84
pubmed: 12704205
J Transl Med. 2016 Jun 07;14(1):161
pubmed: 27268062
Radiology. 2011 Nov;261(2):456-66
pubmed: 21852570
J Magn Reson Imaging. 2016 Sep;44(3):521-40
pubmed: 26892827
Radiology. 1988 Aug;168(2):497-505
pubmed: 3393671
Invest Radiol. 2015 Nov;50(11):792-7
pubmed: 26186280
Invest Radiol. 2017 Sep;52(9):507-513
pubmed: 28379863
J Comput Assist Tomogr. 2016 Sep-Oct;40(5):709-16
pubmed: 27224231
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22
pubmed: 11072146
J Magn Reson Imaging. 2015 Dec;42(6):1532-7
pubmed: 25946483
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Radiother Oncol. 2015 Jul;116(1):94-9
pubmed: 26049919
Magn Reson Imaging. 2018 Jul;50:1-9
pubmed: 29476781
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1052-1062
pubmed: 29891208
J Magn Reson Imaging. 2008 Jun;27(6):1302-8
pubmed: 18504750
Acta Oncol. 2017 Dec;56(12):1754-1762
pubmed: 28661213
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
J Comput Assist Tomogr. 2015 Sep-Oct;39(5):697-701
pubmed: 26176427
PLoS One. 2018 Apr 4;13(4):e0194590
pubmed: 29617445
Gastroenterology. 2018 Dec;155(6):1999-2013.e3
pubmed: 30165049
Invest Radiol. 2013 Mar;48(3):129-33
pubmed: 23296083
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Invest Radiol. 2009 Dec;44(12):769-75
pubmed: 19838121
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Histopathology. 2003 Dec;43(6):550-5
pubmed: 14636255
IEEE Trans Image Process. 1998;7(1):27-41
pubmed: 18267377
J Magn Reson Imaging. 2017 Aug;46(2):393-402
pubmed: 28152252
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1065-71
pubmed: 17637389
APMIS. 2013 Nov;121(11):1037-46
pubmed: 23489215
Invest Radiol. 2016 Apr;51(4):211-20
pubmed: 26646306
Clin Cancer Res. 2017 Mar 15;23(6):1461-1470
pubmed: 27663591
Trials. 2016 Mar 09;17(1):127
pubmed: 26955809
Magn Reson Imaging. 2015 Jul;33(6):737-60
pubmed: 25169584